BioSpace News Archive

Drug Development

Tricida Stocks Plummet Following Trial Failure in Kidney Disease

Top-line data from Tricida’s VALOR-CKD trial showed veverimer failed to meet its primary endpoint and does not slow progression in patients with metabolic acidosis and CKD.

October 24, 2022
·
2 min read
·
Tristan Manalac
Deals

PhaseBio Files for Bankruptcy, Inks Deal to Sell Assets to Unnamed Company (Updated)

PhaseBio plans to file Chapter 11 bankruptcy and sell off its bentracimab assets under a stalking horse arrangement with an unnamed “large pharmaceutical company.”

October 24, 2022
·
3 min read
·
Mark Terry
Drug Development

Scholar Rock Continues to Build Case for SMA Drug with New Data (Updated)

New data from Scholar Rock’s Phase II TOPAZ trial showed its investigational antibody apitegromab improves quality of life in types 2 and 3 spinal muscular atrophy patients.

October 24, 2022
·
3 min read
·
Tristan Manalac
Drug Development

Second Patient Death Shutters Alpine’s Immuno-Oncology Program

Alpine Immune Sciences has voluntarily terminated enrollment in two clinical trials of its immuno-oncology asset, davoceticept, after a second patient death.

October 24, 2022
·
2 min read
·
Mark Terry
Drug Development

Novartis’ PNH Treatment Bests AstraZeneca’s in Phase III Trial

In a Phase III trial comparing Novartis’ experimental iptacopan against AstraZeneca’s Soliris and Ultomiris in paroxysmal nocturnal hemoglobinuria, iptacopan demonstrated superiority.

October 24, 2022
·
2 min read
·
Mark Terry
Business

Sanofi and BioMed X Partner to Predict Efficacy with Virtual Patient Populations

BioMed X and Sanofi have inked an R&D collaboration to use digital data and artificial intelligence to predict the efficacy of first-in-class drug candidates using virtual patient populations.

October 24, 2022
·
2 min read
·
Kaley Lefevre
Drug Development

AstraZeneca’s Imjudo-Imfinzi Combo Scores FDA Approval in Liver Cancer

The FDA greenlit AstraZeneca’s tremelimumab in combination with its checkpoint inhibitor Imfinzi as a treatment for patients with unresectable hepatocellular carcinoma.

October 24, 2022
·
2 min read
·
Alex Keown
Deals

Weeks after Rejecting First Offer, Myovant Agrees to Acquisition by Sumitovant

Myovant Sciences agreed to be acquired by Sumitovant Biopharma for $2.9 billion - three weeks after turning down a previous offer.

October 24, 2022
·
2 min read
·
Alex Keown
Drug Development

Sensorion Announces Approval to Initiate amended Phase 2a Proof of Concept Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity in France

Sensorion announces that the initiation of a Proof of Concept clinical trial of SENS-401 in patients with Cisplatin-Induced Ototoxicity has been approved by regulatory authorities in France.

October 24, 2022
·
5 min read
Drug Development

Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities

Gilead Sciences, Inc. announced the presentation of real-world results from the BICSTaR study, highlighting Biktarvy® as a generally well tolerated and efficacious regimen regardless of prior treatment and comorbidity status in people with HIV.

October 24, 2022
·
13 min read